Rammes Gerhard, Rupprecht Rainer
Max-Planck-Institute of Psychiatry, Kraepelinstrasse 2-10, Munich, 80804, Germany.
Mol Neurobiol. 2007 Apr;35(2):160-74. doi: 10.1007/s12035-007-0006-1.
It is generally accepted that antidepressants and antipsychotics mediate their therapeutic effects via specific interaction with processes related to synaptic neurotransmission in the central nervous system. Besides their well-known classical mechanisms of action, antidepressants and antipsychotics show widely unknown effects, which might also contribute to the pharmacological profile of these agents. There is growing evidence that an interaction of these drugs with allosteric modulatory sites of ligand-gated ion channels (LGICs) might represent a yet unknown principle of action. Such interactions of psychopharmacological drugs with LGICs might play an important role both for the therapeutic efficacy and the side effect profile of these agents. In this review, we focus on the direct interaction of antidepressants and antipsychotics with LGICs, which may provide a basis for the development of novel psychopharmacological drugs.
人们普遍认为,抗抑郁药和抗精神病药通过与中枢神经系统中与突触神经传递相关的过程进行特异性相互作用来介导其治疗效果。除了其众所周知的经典作用机制外,抗抑郁药和抗精神病药还表现出广泛未知的效应,这些效应也可能有助于这些药物的药理学特征。越来越多的证据表明,这些药物与配体门控离子通道(LGICs)的变构调节位点相互作用可能代表一种尚未被发现的作用原理。精神药理学药物与LGICs的这种相互作用可能对这些药物的治疗效果和副作用特征都起着重要作用。在这篇综述中,我们聚焦于抗抑郁药和抗精神病药与LGICs的直接相互作用,这可能为新型精神药理学药物的开发提供基础。